补肾活血方联合缬沙坦胶囊治疗糖尿病肾病Ⅲ期30例  

Kidney-tonifying Blood-activating Prescription Combined with Valsartan Capsules in Treating 30 Cases of Diabetic Nephropathy at Stage Ⅲ

作　　者：张新丽[1] 靳锋[1] 丁文君[1] 王文海[1] 

机构地区：[1]甘肃省中医院肾病科,甘肃兰州730050

出　　处：《西部中医药》2017年第10期99-102,共4页Western Journal of Traditional Chinese Medicine

摘　　要：目的:观察补肾活血方联合缬沙坦胶囊治疗2型糖尿病肾病(diabetic nephropathy,DN)Ⅲ期的临床疗效。方法:将62例患者随机分为对照组32例、观察组30例,2组均服用缬沙坦胶囊,观察组加服补肾活血方,2组均连续治疗2个月。观察2组治疗前后中医证候积分,餐前血糖(FBG)、餐后2小时血糖(2h PBG)、糖化血红蛋白(HbA_(1c))、尿微量白蛋白排泄率、白介素6(IL-6)、肿瘤坏死因子α(TNF-α)、尿白蛋白排泄率(UAER)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等指标的变化情况。结果:总有效率观察组为86.67%,对照组为59.37%,2组比较差异有统计学意义(P<0.05);中医证候总积分治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后组间比较,差异也有统计学意义(P<0.05)。FBG、2h PBG及Hb A1c治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后组间比较,差异无统计学意义(P>0.05)。观察组IL-6、TNF-α及UAER治疗前后比较,差异有统计学意义(P<0.05);对照组UAER治疗前后比较,差异有统计学意义(P<0.05),IL-6、TNF-α治疗前后比较,差异无统计学意义(P>0.05)。IL-6、TNF-α及UAER治疗后2组组间比较,差异有统计学意义(P<0.05)。TC、TG、HDL-C、LDL-C治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后组间比较,差异有统计学意义(P<0.05)。AST、ALT、BUN及SCr治疗前后组内及治疗后组间比较,差异均无统计学意义(P>0.05)。结论:补肾活血方联合缬沙坦胶囊治疗Ⅲ期DN可明显改善临床症状,以减少尿蛋白的排泄,减轻炎症反应,延缓DN的进展,且安全、有效。Objective：To observe clinical effects of kidney-tonifying blood-activating prescription combined with valsartan capsules in treating diabetic nephropathy （DN） at stage Ⅲ.Methods：Sixty-two patients were randomized into 32 cases of the control group and 30 cases of the observation group,both groups took valsartan capsules,the observation group took kidney-tonifying blood-activating prescription,both groups were treated for two months consecutively.TCM syndrome scales of both groups were observed before and after treating,FBG,2hPBG,HbA1c,urinary microalbumin excretion rate （UMER）,IL-6,TNF-α,urinary albumin excretion rate （UAER）,TC,TG,HDL-C,LDL-C and others were detected.Results：Total effective rate of the observation group was 86.67%,higher than 59.37% of the control group,and the difference had statistical meaning （P〈0.05）;the difference presented statistical meaning in the comparisons of TCM syndrome scales before and after treating within one group （P〈0.05）;the difference presented statistical meaning in the comparisons of TCM syndrome scales after treating between two groups （P〈0.05）.The difference had statistical meaning in the comparison ofFBG,2hPBG and HbA1c before and after treating within one group （P〈0.05）;the difference had no statistical meaning in the comparisons between both groups after treating （P〉0.05）.The difference had statistical meaning in the comparisons of IL-6,TNF-α and UAER before and after treating within the observation group （P〈0.05）;and the difference presented statistical meaning in the comparisons of UAER before and after treating within the control group （P〈0.05）;the difference had no statistical meaning in the comparison ofIL-6 and TNF-α before and after treating （P〉0.05）.The difference had statistical meaning in the comparisons of IL-6,TNF-α and UAER between both groups after treating （P〈0.05）.The difference had statistical meaning in the comparisons of TC,TG,HDL-C and LDL-C before and after treating withi

关 键 词：糖尿病肾病 Ⅲ期 补肾活血方 白介素6 肿瘤坏死因子Α 

分 类 号：R587.2[医药卫生—内分泌]